IR@PKUHSC  > 北京大学第二临床医学院  > 眼科
学科主题临床医学
Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study
Hou Jing; Tao Yong; Jiang Yan-rong; Li Xiao-xin; Gao Lei
关键词bevacizumab branch retinal vein occlusion triamcinolone acetonide
刊名CHINESE MEDICAL JOURNAL
2009-11-20
DOI10.3760/cma.j.issn.0366-6999.2009.22.004
122期:22页:2695-2699
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Beijing Natural Science Foundation ; Beijing Natural Science Foundation
研究领域[WOS]General & Internal Medicine
关键词[WOS]INTRAOCULAR-PRESSURE ELEVATION ; NEOVASCULAR DISEASES ; SECONDARY ; AVASTIN ; INJECTION
英文摘要

Background Branch retinal vein occlusion (BRVO) is a common retinal vascular disorder of the elderly and both intravitreal triamcinolone acetonide (TA) and intravitreal bevacizumab were reported to be effective. The purpose of this study was to compare intravitreal bevacizumab with intravitreal TA for the treatment of macular edema resulting from BRVO.

Methods The retrospectively comparative interventional study included a bevacizumab group of 34 BRVO patients (1.25 mg bevacizumab) and a TA group of 34 BRVO patients (4.0 mg TA), and the two groups were matched by baseline best corrected visual acuity (BCVA). Examinations were designed to be carried out at 1 day, 3 days, 1 month, 2 months, 3 months, 6 months and 1 year after each injection. The mean follow-up was (148.43 +/- 130.56) days. Main outcome parameters were BCVA and morphometric measurements of the macula obtained by optical coherence tomography.

Results In all follow-ups, the mean changes of BCVA (LogMAR) between two groups were not significantly different (P>0.10). Similarly, the rates of patients who got BCVA improvement >= 2 lines or lost BCVA >= 2 lines were not significantly different, either (P>0.10). In both groups, compared with baseline, the mean central macular thickness (CMT) got reduction from 4 weeks to 1 year after initial injection, however, which lost statistical significance at 6-month follow-up in TA group (P=0.25) and lost significance at 3-month and 6-month follow-up in bevacizumab group (P=0.07, 0.21). The mean CMT between two groups differed at 3-month follow-up (P<0.01), while almost kept parallel in other follow-ups (all P>0.40). In TA group, retinal pigment epithelium tear occurred in 1 eye at 8 weeks after initial injection and 12 eyes (35.3%) got intraocular pressure >21 mmHg. In bevacizumab group, no severe complications were observed.

Conclusion For BRVO, intravitreal bevacizumab versus intravitreal TA causes a similar increase in visual acuity and reduction of macular edema (except 3-month follow-up) with minor complications during 1 year. Chin Med J 2009;122(22):2695-2699

语种英语
所属项目编号7062065
资助者Beijing Natural Science Foundation ; Beijing Natural Science Foundation
WOS记录号WOS:000272580300004
引用统计
被引频次:22[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66293
专题北京大学第二临床医学院_眼科
作者单位Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Hou Jing,Tao Yong,Jiang Yan-rong,et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study[J]. CHINESE MEDICAL JOURNAL,2009,122(22):2695-2699.
APA Hou Jing,Tao Yong,Jiang Yan-rong,Li Xiao-xin,&Gao Lei.(2009).Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.CHINESE MEDICAL JOURNAL,122(22),2695-2699.
MLA Hou Jing,et al."Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study".CHINESE MEDICAL JOURNAL 122.22(2009):2695-2699.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hou Jing]的文章
[Tao Yong]的文章
[Jiang Yan-rong]的文章
百度学术
百度学术中相似的文章
[Hou Jing]的文章
[Tao Yong]的文章
[Jiang Yan-rong]的文章
必应学术
必应学术中相似的文章
[Hou Jing]的文章
[Tao Yong]的文章
[Jiang Yan-rong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。